Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

819
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
819
Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Tumor Progression02:07

Tumor Progression

3.5K
3.5K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

696
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
696
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

403
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
403
Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

1.7K
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL.

Journal of hematology & oncology·2016
Same author

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

Blood cancer journal·2016
Same author

Prof. Thomas Büchner (22 September 1934-5 August 2016)-A leading European hematologist and AML trialist.

Leukemia·2016
Same author

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.

Leukemia·2016
Same author

Detection of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia by Analysis of Gene Rearrangements and Correlation with Early Relapses.

Leukemia & lymphoma·2016
Same journal

Deconvoluting MLL1-dependent pathways in hematopoiesis and leukemogenesis.

Leukemia supplements·2016
Same journal

New Abelson interactor-1 (Abi-1)-driven mechanism of acquired drug resistance.

Leukemia supplements·2016
Same journal

STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.

Leukemia supplements·2016
Same journal

Dissecting reprogramming, differentiation and conversion with network biology.

Leukemia supplements·2016
Same journal

Insights into the pathophysiology and therapy of myeloproliferative neoplasms from mouse models.

Leukemia supplements·2016
Same journal

Myeloid differentiation and the leukemia-initiating cell.

Leukemia supplements·2016
See all related articles

Related Experiment Video

Updated: Mar 21, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K

Change in prognostic factors.

D Hoelzer1, N Gökbuget1

  • 1Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital , Frankfurt, Germany.

Leukemia Supplements
|May 14, 2016
PubMed
Summary
This summary is machine-generated.

Evaluating prognostic factors in acute lymphoblastic leukemia helps stratify patients into risk groups. This guides treatment decisions and predicts disease-free and overall survival outcomes.

Keywords:
acute lymphoblastic leukemiaminimal residual diseaseprognostic factorsrisk stratificationtargeted therapies

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

998

Related Experiment Videos

Last Updated: Mar 21, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

998

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Acute lymphoblastic leukemia (ALL) requires accurate prognostic assessment for effective management.
  • Identifying prognostic factors is crucial for tailoring treatment strategies in ALL patients.

Purpose of the Study:

  • To stratify acute lymphoblastic leukemia patients into distinct risk groups (adverse vs. good).
  • To inform the selection of appropriate and individualized treatment options based on risk stratification.
  • To evaluate the impact of prognostic factors on patient outcomes, specifically disease-free and overall survival.

Main Methods:

  • Analysis of established and novel prognostic factors in acute lymphoblastic leukemia cohorts.
  • Statistical modeling to correlate prognostic factors with patient outcomes.
  • Risk group assignment based on identified prognostic indicators.

Main Results:

  • Prognostic factors significantly differentiate patients into adverse- and good-risk categories.
  • Specific factors demonstrate a strong correlation with disease-free survival.
  • Key indicators are identified for predicting overall survival in acute lymphoblastic leukemia.

Conclusions:

  • Prognostic factor evaluation is essential for personalized medicine in acute lymphoblastic leukemia.
  • Accurate risk stratification improves treatment selection and optimizes patient outcomes.
  • Continued research into prognostic factors enhances the management of acute lymphoblastic leukemia.